Antifungals in pulmonary infections: to whom, when and how?

Sebastian R. Ott

Source: Eur Respir Monogr 2017; 75: 159-184
Disease area: Respiratory infections

Congress or journal article abstractFull text journal article

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Sebastian R. Ott. Antifungals in pulmonary infections: to whom, when and how?. Eur Respir Monogr 2017; 75: 159-184

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Pulmonary rehabilitation for bronchiectasis: if not now, when?
Source: Eur Respir J, 53 (1) 1802474; 10.1183/13993003.02474-2018
Year: 2019

Thrombo-embolic pulmonary hypertension: which treatment should we choose? / Hypertension pulmonaire thrombo-embolique: quel traitement choisir ?
Source: International Congress 2018 – French Programme 2018: Part II
Year: 2018

Antibiotics for pulmonary infections: an overview
Source: Eur Respir Monogr 2017; 75: 1-20
Year: 2017

Cured pulmonary tuberculosis population: what is next?
Source: Virtual Congress 2020 – Pulmonary function and rehabilitation in non-respiratory disease
Year: 2020

Pulmonary infections in HIV-infected patients: an update in the 21st century
Source: Eur Respir J 2012; 39: 730-745
Year: 2012

Image-based recommendations for the evaluation of pulmonary embolism and arterial hypertension: what? when? how?
Source: Virtual Congress 2020 – Image-based guidelines and recommendations in respiratory diseases
Year: 2020

Diagnosis and treatment of pulmonary hypertension in COPD patients: how far should we go?
Source: International Congress 2019 – Lung vessels in COPD: it is time to take them seriously!
Year: 2019

Patients with recurrent tuberculosis in Istanbul: reactivation?, reinfection?
Source: International Congress 2018 – Diagnosis of tuberculosis
Year: 2018

Pneumonectomy in pulmonary tuberculosis. To do or not to do?
Source: Annual Congress 2012 - Tuberculosis: invasive diagnostic and therapeutic interventions
Year: 2012

Bronchial inflammation, respiratory symptoms and lung function in patients who finished treatment for pulmonary tuberculosis: is it the beginning of a new disease?
Source: International Congress 2019 – Clinical aspects of airway diseases
Year: 2019

How important is work as a risk for lung infections? A story of tuberculosis and pneumonia
Source: Virtual Congress 2020 – How much lung disease is really caused by work, and how to assess the worker who wishes to continue working?
Year: 2020

Treatment of pulmonary hypertension due to COPD: can we really hope in better?
Source: Eur Respir J 2005; 26: Suppl. 49, 562s
Year: 2005

Pulmonary infection with nocardia species in chronic respiratory patients: a report of 12 cases
Source: Eur Respir J 2006; 28: Suppl. 50, 560s
Year: 2006

Pulmonary aspergillosis: a clinical review
Source: Eur Respir Rev 2011; 20: 156-174
Year: 2011

IPC-related pleural infection vs. colonisation - to treat or not to treat?
Source: International Congress 2019 – Pleural infection and complicated pneumonia
Year: 2019

Pulmonary infections: what to do when it's a bug that you do not know
Source: Eur Respir J 2003; 21: 201
Year: 2003

Pulmonary hypertension: what can we learn from studies?
Source: International Congress 2015 – Practising personalised medicine: why, when, and how?
Year: 2015